Fig. 7
From: Metformin alters therapeutic effects in the BALB/c tumor therapy model
Metformin alters glucose consumption in the BALB-TTM. The BALB/c 3 T3 cell transformation assay was performed as described earlier. An additional treatment was conducted from day 32–35 with metformin. On day 35 and 38, fresh medium without metformin was added again. Control cells were not treated with MCA/TPA. Medium supernatant was collected at day 32, 33, 34, 35, 38 and 42 and glucose concentration was measured. The slanting lines indicate the decrease of glucose after fresh medium with 3.15 g/l D-glucose was added every 3–4 days. Statistical differences were calculated with a one-way ANOVA (post-hoc: Bonferroni) with * = (p < 0.05) and ** = (p < 0.01) vs. control for each point in time